$TPST

Tempest Therapeutics, Inc. (TPST) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001544227 0001544227 2026-07-27 2026-07-27 0001544227 us-gaap:CommonStockMember 2026-07-27 2026-07-27 0001544227 us-gaap:SeriesAPreferredStockMember 2026-07-27 2026-07-27 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pu

Tempest Therapeutics, Inc. (TPST) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 d107304dex101.htm EX-10.1 EX-10.1 Exhibit 10.1 PRODUCT DEVELOPMENT AND INVESTIGATOR-INITIATED TRIAL (IIT) COLLABORATION AGREEMENT This Product Development and Investigator-Initiated Trial (IIT) Collaboration Agreement (this “Agreement”) is entered into as of July 17, 20

Tempest Therapeutics (Nasdaq: TPST) said it will advance TPST-4003, its CD7-targeted mRNA/LNP in vivo CAR-T using a dual CD19/BCMA CAR, into a first investigator-initiated trial in nervous system autoimmune diseases. The study plans about 10 patients with MG and MS, with first dosing expected in Q4 2026 and initial data in H1 2027.

Angel Matthew (CEO and President) purchased 231,482 indirectly-held shares of Tempest Therapeutics, Inc. (TPST) at $2.16 ($0.50M total) on 2026-03-24.

Tempest Therapeutics, Inc. (TPST) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001544227 0001544227 2026-06-18 2026-06-18 0001544227 us-gaap:CommonStockMember 2026-06-18 2026-06-18 0001544227 us-gaap:SeriesAPreferredStockMember 2026-06-18 2026-06-18 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pu

Tempest Therapeutics (NASDAQ:TPST) has received a notice from Nasdaq regarding listing deficiencies. The company is not in compliance with Nasdaq's minimum stockholders’ equity requirement and also faces issues with independent directors and board committees due to recent resignations. Tempest Therapeutics has 45 days to submit a plan to regain compliance, but these notifications do not immediately affect the trading of its common stock.

Existing shareholders of biopharmaceutical company Tempest Therapeutics Inc. plan to resell up to 8.27 million shares of common stock, as disclosed in a recent SEC filing. This move is a proactive effort by the selling shareholders to exit partial investments, with the company itself not receiving any direct financing proceeds from the resale. Tempest Therapeutics, an oncology therapeutic company, noted that the specific transactions will occur based on market conditions, potentially drawing attention to its capital structure.

Tempest Therapeutics (NASDAQ: TPST) has registered 8,268,495 shares of common stock for resale by existing selling stockholders. These shares were issued as consideration in an Asset Purchase Agreement dated November 19, 2025, for the acquisition of CAR-T and related assets. The company will not receive any proceeds from these resales, which will be conducted by the named selling stockholders, including Matthew Angel and Lotus Capital (BVI) Limited.

Tempest Therapeutics has announced January 30, 2026, as the record date for the distribution of warrants to purchase its common stock, with the distribution expected on February 3, 2026. This move follows an Asset Purchase Agreement and is contingent on stockholder approval. Each stockholder will receive one warrant per share, exercisable at $18.48 for five years, as part of the company's strategy to advance its cancer treatment pipeline.

$4.25 million upfront with up to an additional $4.1 million of potential aggregate gross proceeds upon the exercise in full of short-term unregistered warrants $4.25 million upfront with up to an additional $4.1 million of potential aggregate gross proceeds upon the exercise in full of ...